 SAN JOSE, Calif., July 30, 2021 GLOBE NEWSWIRE -- Rani Therapeutics Holdings, Inc. Rani Therapeutics or Rani, a clinical stage biotherapeutics company focused on advancing technologies to enable the development of orally administered biologics, today announced the pricing of its initial public offering of 6,666,667 shares of Class A common stock at a price to the public of 11.00 per share. The gross proceeds to Rani from the offering, before deducting underwriting discounts and commissions and estimated offering expenses, are expected to be 73.3 million. In addition, Rani has granted the underwriters a 30-day option to purchase up to an additional 1,000,000 shares of Class A common stock at the initial public offering price, less underwriting discounts and commissions. The shares are expected to begin trading on the Nasdaq Global Market under the ticker symbol RANI on July 30, 2021. The offering is expected to close on August 3, 2021, subject to the satisfaction of customary closing conditions. 